Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer

Micro-Abstract Eribulin plus capecitabine as adjuvant therapy was feasible in postmenopausal women with early-stage, human epidermal growth factor receptor 2-negative, estrogen receptor-positive breast cancer. The mean relative dose intensity was 90.6%, and the feasibility rate was 81.3% with the st...

Full description

Saved in:
Bibliographic Details
Published in:Clinical breast cancer 2016-02, Vol.16 (1), p.31-37
Main Authors: Smith, John W, Vukelja, Svetislava, Hoffman, Anthony D, Jones, Vicky E, McIntyre, Kristi, Berrak, Erhan, Song, James X, O'Shaughnessy, Joyce
Format: Article
Language:English
Subjects:
Adjuvant therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy
Capecitabine - administration & dosage
Capecitabine - adverse effects
Chemotherapy
Chemotherapy, Adjuvant - methods
ER-positive
Feasibility Studies
Female
Furans - administration & dosage
Furans - adverse effects
Halaven
Hematology, Oncology and Palliative Medicine
HER2-negative
Humans
Ketones - administration & dosage
Ketones - adverse effects
Middle Aged
Neoplasm Staging
Obstetrics and Gynecology
Postmenopause
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Eribulin plus capecitabine as adjuvant therapy was feasible in postmenopausal women with early-stage, human epidermal growth factor receptor 2-negative, estrogen receptor-positive breast cancer. The mean relative dose intensity was 90.6%, and the feasibility rate was 81.3% with the standard dosing schedule for both drugs. An alternative schedule for capecitabine (7 days on, 7 days off) was better tolerated in a supplemental group of 10 patients.
ISSN:1526-8209
1938-0666
DOI:10.1016/j.clbc.2015.07.007